Revenue and operating income declined year-over-year due to the sale of Chinese subsidiaries, with net income supported by discontinued operations. The company approved a split to separate the foaming agent business, and maintains a strong balance sheet with robust R&D investment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.